On Thursday, Shares of General Growth Properties, Inc (NYSE:GGP), gained 3.14% to $28.29.
On April 27, General Growth Properties, stated results for the three months ended March 31, 2015.
For the Three Months Ended March 31, 2015
Comparable net operating income (“Same Store NOI”) raised 3.3% to $543 million from $525 million in the preceding year period.
Company earnings before interest, taxes, depreciation and amortization (“Company EBITDA”) raised 4.2% to $502 million from $482 million in the preceding year period.
Company funds from operations (“Company FFO”) per share raised 4.9% to $0.32 per diluted share from $0.31 per diluted share in the preceding year period. Company FFO raised 5.8% to $309 million from $292 million in the preceding year period.
Net income attributable to common stockholders, which is influenced primarily by depreciation expense and gain from change in control of investment properties, was $631 million, or $0.66 per diluted share, as contrast to net income of $124 million, or $0.13 per diluted share, in the preceding year period.
General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.
At the end of Thursday’s trade, Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX), lost -0.20% to $5.01.
Orexigen Therapeutics, issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that contrast the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, and an update on its Contrave partnership with Takeda Pharmaceuticals Company.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a partnership agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Finally, Symantec Corporation (NASDAQ:SYMC), ended its last trade with 2.29% gain, and closed at $25.90.
Symantec Corporation, stated the results of its fourth quarter and fiscal year 2015, ended April 3, 2015.
Symantec’s Board of Directors has declared a quarterly cash dividend of $0.15 per common share to be paid on June 24, 2015 to all shareholders of record as of the close of business on June 10, 2015. The ex-dividend date will be June 8, 2015.
Symantec Corporation, together with its auxiliaries, provides security, backup, and availability solutions worldwide. Its products and services protect people and information in any environment from mobile devices and enterprise data centers to cloud-based systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
